LPTX Leap Therapeutics Inc
Price (delayed)
$0.3982
Market cap
$15.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.67
Enterprise value
-$48.43M
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator.
Highlights
LPTX's debt has dropped by 100% since the previous quarter
The EPS has surged by 71% year-on-year and by 4% since the previous quarter
Leap Therapeutics's net income has increased by 20% YoY but it has decreased by 7% from the previous quarter
The quick ratio is down by 46% year-on-year and by 22% since the previous quarter
The equity has declined by 32% year-on-year and by 26% since the previous quarter
Key stats
What are the main financial stats of LPTX
Market
Valuations
Earnings
Shares outstanding
38.32M
Market cap
$15.26M
Enterprise value
-$48.43M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.31
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$68.75M
Net income
-$64.59M
EBIT
-$63.88M
EBITDA
-$63.87M
Free cash flow
-$55.17M
Per share
Balance sheet
Liquidity
EPS
-$1.67
EPS diluted
-$1.67
Free cash flow per share
-$1.34
Book value per share
$1.28
Revenue per share
$0
TBVPS
$1.58
Total assets
$65.05M
Total liabilities
$16.09M
Debt
$0
Equity
$48.95M
Working capital
$47.72M
Debt to equity
0
Current ratio
3.97
Quick ratio
4.01
Net debt/EBITDA
1
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-93.5%
Return on equity
-116.7%
Return on invested capital
N/A
Return on capital employed
-130.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LPTX stock price
How has the Leap Therapeutics stock price performed over time
Intraday
-1.56%
1 week
-9.56%
1 month
-21.61%
1 year
-82.61%
YTD
-86.15%
QTD
-86.15%
Financial performance
How have Leap Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$68.75M
Net income
-$64.59M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 20% YoY but it fell by 4.6% QoQ
Leap Therapeutics's net income has increased by 20% YoY but it has decreased by 7% from the previous quarter
Growth
What is Leap Therapeutics's growth rate over time
Valuation
What is Leap Therapeutics stock price valuation
P/E
N/A
P/B
0.31
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 71% year-on-year and by 4% since the previous quarter
LPTX's P/B is 82% below its 5-year quarterly average of 1.8 and 80% below its last 4 quarters average of 1.6
The equity has declined by 32% year-on-year and by 26% since the previous quarter
Efficiency
How efficient is Leap Therapeutics business performance
The return on equity has declined by 19% since the previous quarter but it has increased by 12% year-on-year
The ROA has contracted by 14% from the previous quarter and by 2.6% YoY
Dividends
What is LPTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LPTX.
Financial health
How did Leap Therapeutics financials performed over time
The current ratio has declined by 46% year-on-year and by 22% since the previous quarter
LPTX's total liabilities is up by 46% YoY and by 2.9% from the previous quarter
LPTX's debt is 100% smaller than its equity
LPTX's debt has dropped by 100% since the previous quarter
The equity has declined by 32% year-on-year and by 26% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.